Alzheimer’s disease (AD) co-pathology is common in dementia with Lewy bodies (DLB) and has been linked to poorer outcomes. However, its associations with domain-specific cognitive performance across the MCI/prodromal and dementia stages, and the relationship between cognitive performance and plasma biomarkers, re...
Elena Vera-Campuzano, Í. Rodríguez-Baz, Carla Abdelnour et al.· Alzheimer's Research & T...· 0 citations
White matter signal abnormalities (WMSA) on MRI are common in dementia with Lewy bodies (DLB), and more severe WMSA have been associated with increased neurodegeneration in DLB. However, the underlying mechanisms of WMSA remain unclear. Single-Shell 3-Tissue Constrained Spherical Deconvolution (SS3T-CSD) is a d...
Anna Rennie, M. Němý, A. Badji et al.· Alzheimer's Research & T...· 0 citations
BACKGROUND
As individuals with Down syndrome age, they face high risks of Alzheimer's disease and epilepsy. With symptomatic Alzheimer's disease, late-onset myoclonic epilepsy in Down syndrome (LOMEDS) often emerges. We aimed to examine how epilepsy develops in Down syndrome, its timing relative to Alzheimer's disease...
Lucía Maure-Blesa, M. Carmona-Iragui, I. Barroeta et al.· The Lancet· 1 citation
There is a need for early, objective markers of Alzheimer's disease (AD)‐related synapse dysfunction in adults with Down syndrome (DS). The presynaptic protein β‐synuclein is elevated in the blood of adults with DS. This study evaluates the positioning of these changes relative to changes in pathophysiological blood bi...
Alba Cervantes González, A. Morcillo-Nieto, Sara Serrano et al.· Alzheimer's & Dementia· 0 citations
Heterogeneous pre-dementia trajectories are revealed and support is shown for combining α-synuclein detection with Alzheimer biomarkers, cognitive staging and multidomain clinical measures to improve prognosis and trial design are supported.
I. Illán-Gala, E. Vera, J. Selma-González et al.· Research Square· 0 citations
These findings highlight the complementary roles of CSF and plasma tau biomarkers in tracking disease progression: CSF biomarkers capture early pathological changes, whereas plasma biomarkers more effectively reflect disease progression within symptomatic stages.
J. Arranz, J. Lantero-Rodríguez, Luisa Sophie Braun-Wohlfahrt et al.· EBioMedicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
